ArticlePloS one2011
Broad-spectrum antiviral therapeutics.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04420260 (Scheme of Primary Prevention of Infection by COVID-19, in Workers), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia
Who cites it
28 citing papers in PubMed, 77 citations in OpenAlex.
- Protein-Linker Co-engineering for Broad-Spectrum Antiviral Development against Enveloped Viruses.ACS materials letters · 2026Article
- Deep learning in the discovery of antiviral peptides and peptidomimetics: databases and prediction tools.Molecular diversity · 2025Review
- A hybrid framework of generative deep learning for antiviral peptide discovery.Scientific reports · 2025Article
- Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals.International journal of peptide research and therapeutics · 2023Review
- Apoptosis during ZIKA Virus Infection: Too Soon or Too Late?International journal of molecular sciences · 2022Review
- Human coronaviruses and therapeutic drug discovery.Infectious diseases of poverty · 2021Review
- Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.European journal of pharmacology · 2020Review
- Current scenario of COVID-19 in pediatric age group and physiology of immune and thymus response.Saudi journal of biological sciences · 2020Review
- Opportunities for biomaterials to address the challenges of COVID-19.Journal of biomedical materials research. Part A · 2020Review
- Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.Signal transduction and targeted therapy · 2020Review
- SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries.Vaccines · 2020Review
- Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children.The Pediatric infectious disease journal · 2020Review
- Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options.Journal of clinical microbiology · 2020Review
- The role of death domain proteins in host response upon SARS-CoV-2 infection: modulation of programmed cell death and translational applications.Cell death discovery · 2020Review
- The Threat and Response to Infectious Diseases (Revised).Microbial ecology · 2018Review
- Pediatrics in 21Indian journal of pediatrics · 2016Article
- Coronaviruses - drug discovery and therapeutic options.Nature reviews. Drug discovery · 2016Review
- Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2015Article
- The expanding roles of endoplasmic reticulum stress in virus replication and pathogenesis.Critical reviews in microbiology · 2015Review
- Broad-spectrum antiviral agents.Frontiers in microbiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Currently there are relatively few antiviral therapeutics, and most which do exist are highly pathogen-specific or have other disadvantages. We have developed a new broad-spectrum antiviral approach, dubbed Double-stranded RNA (dsRNA) Activated Caspase Oligomerizer (DRACO) that selectively induces apoptosis in cells containing viral dsRNA, rapidly killing infected cells without harming uninfected cells. We have created DRACOs and shown that they are nontoxic in 11 mammalian cell types and effective against 15 different viruses, including dengue flavivirus, Amapari and Tacaribe arenaviruses, Guama bunyavirus, and H1N1 influenza. We have also demonstrated that DRACOs can rescue mice challenged with H1N1 influenza. DRACOs have the potential to be effective therapeutics or prophylactics for numerous clinical and priority viruses, due to the broad-spectrum sensitivity of the dsRNA detection domain, the potent activity of the apoptosis induction domain, and the novel direct linkage between the two which viruses have never encountered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.